<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CONTEXT: <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">Antiphospholipid syndrome</z:e> (APS, or Hughes' syndrome) is a systemic <z:e sem="disease" ids="C0004364" disease_type="Disease or Syndrome" abbrv="">autoimmune disorder</z:e> characterized by <z:hpo ids='HP_0003613'>antiphospholipid antibody positivity</z:hpo>, which may lead to arterial and/or <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0598608" disease_type="Disease or Syndrome" abbrv="">Hyperhomocysteinemia</z:e> (HHcy), variously associated with 5,10-<z:chebi fb="13" ids="29357,29358">methylene</z:chebi> <z:chebi fb="0" ids="20506,26907">tetrahydrofolate</z:chebi> reductase (MTHFR) gene point mutations, is also implicated in <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The association of APS and HHcy has already been described but has never been reported in patients with <z:mp ids='MP_0002538'>DiGeorge syndrome</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DGS</z:e>), the most common contiguous-gene deletion syndrome (22q11.2) in humans, whose phenotype conversely includes <z:mp ids='MP_0001914'>bleeding</z:mp> disorders </plain></SENT>
<SENT sid="3" pm="."><plain>DATA ACQUISITION: In this report, we present the case of a 19-yr-old patient with a past medical history of <z:e sem="disease" ids="C0751265" disease_type="Mental or Behavioral Dysfunction" abbrv="">learning disability</z:e> and <z:hpo ids='HP_0001513'>obesity</z:hpo> affected with idiopathic <z:hpo ids='HP_0000829'>hypoparathyroidism</z:hpo>, <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, and diffuse <z:hpo ids='HP_0002633'>vasculitis</z:hpo> disorders </plain></SENT>
<SENT sid="4" pm="."><plain>He was referred to our endocrinology clinic for the management of severe <z:hpo ids='HP_0002901'>hypocalcemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>At the time of presentation he had been taking <z:chebi fb="0" ids="35623">antiepileptic</z:chebi> drugs for 2 wk and displayed <z:hpo ids='HP_0001999'>facial dysmorphism</z:hpo> (<z:hpo ids='HP_0000470'>short neck</z:hpo>, <z:hpo ids='HP_0000347'>micrognathia</z:hpo>, a small mouth, <z:hpo ids='HP_0000430'>hypoplastic nasal alae</z:hpo>, eye <z:hpo ids='HP_0000316'>hypertelorism</z:hpo>, and low-set <z:hpo ids='HP_0000377'>simple ears</z:hpo>) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DGS</z:e> was suspected and confirmed by both fluorescence in situ hybridization analysis and single nucleotide polymorphism-array analysis, which revealed contiguous gene microdeletion of the chromosome 22q11.2 in the minimal DiGeorge critical region, specifically at the gene locus D22S75 (N25) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: APS, revealed by anti-beta-2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> and anti-prothrombin antibodies positivity, and moderate HHcy related to heterozygous C677T and A1298C point mutations of the MTHFR gene were identified as a possible cause of thrombotic disorder responsible for the widespread presence of cutaneous and <z:e sem="disease" ids="C0221505" disease_type="Disease or Syndrome" abbrv="">cerebral lesions</z:e> </plain></SENT>
</text></document>